Data Insights

Zanidatamab by Jazz Pharmaceuticals for Breast Cancer: Likelihood of Approval

Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Breast Cancer

Data Insights

Zanidatamab by Jazz Pharmaceuticals for Bladder Cancer: Likelihood of Approval

Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Bladder Cancer

Data Insights

Zanidatamab by Jazz Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval

Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Pancreatic Cancer

Data Insights

Lurbinectedin by Jazz Pharmaceuticals for Neuroendocrine Carcinoma: Likelihood of Approval

Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Neuroendocrine Carcinoma

Data Insights

Zanidatamab by Jazz Pharmaceuticals for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Lurbinectedin by Jazz Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

Lurbinectedin by Jazz Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval

Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Metastatic Biliary Tract Cancer

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Colorectal Cancer

Data Insights

JZP-898 by Jazz Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Renal Cell Carcinoma: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Renal Cell Carcinoma

Data Insights

JZP-898 by Jazz Pharmaceuticals for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Gastroesophageal (GE) Junction Carcinomas

Data Insights

JZP-898 by Jazz Pharmaceuticals for Solid Tumor: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Solid Tumor

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Melanoma: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Melanoma

Data Insights

JZP-898 by Jazz Pharmaceuticals for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

Defibrotide sodium by Jazz Pharmaceuticals for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease): Likelihood of Approval

Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Mucocutaneous Lymph Node Syndrome (Kawasaki...

Likelihood of Approval and Phase Transition Success Rate Model - Defibrotide Sodium in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)

Data Insights

JZP-898 by Jazz Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

JZP-898 is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - JZP-898 in Non-Small Cell Lung Cancer

Data Insights

Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals's Zanidatamab?

Zanidatamab is a monoclonal antibody commercialized by Jazz Pharmaceuticals, with a leading Pre-Registration program in Metastatic Biliary Tract Cancer. According...

Net Present Value Model: Jazz Pharmaceuticals Plc's Zanidatamab

Data Insights

Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals's JZP-898?

JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...

Net Present Value Model: Jazz Pharmaceuticals Plc's JZP-898

Data Insights

Defibrotide sodium by Jazz Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval

Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Sickle Cell Disease. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Defibrotide Sodium in Sickle Cell Disease